Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Other Non-Current Assets (2020 - 2025)

Candel Therapeutics' Other Non-Current Assets history spans 4 years, with the latest figure at $300000.0 for Q4 2023.

  • On a quarterly basis, Other Non-Current Assets rose 12.78% to $300000.0 in Q4 2023 year-over-year; TTM through Dec 2023 was $300000.0, a 12.78% increase, with the full-year FY2023 number at $300000.0, up 12.78% from a year prior.
  • Other Non-Current Assets hit $300000.0 in Q4 2023 for Candel Therapeutics, up from $139000.0 in the prior quarter.
  • Over the last five years, Other Non-Current Assets for CADL hit a ceiling of $1.7 million in Q2 2021 and a floor of $139000.0 in Q3 2023.
  • Historically, Other Non-Current Assets has averaged $427000.0 across 4 years, with a median of $300000.0 in 2023.
  • Biggest five-year swings in Other Non-Current Assets: rose 14.61% in 2021 and later crashed 84.46% in 2022.
  • Tracing CADL's Other Non-Current Assets over 4 years: stood at $349000.0 in 2020, then rose by 14.61% to $400000.0 in 2021, then tumbled by 33.5% to $266000.0 in 2022, then increased by 12.78% to $300000.0 in 2023.
  • Business Quant data shows Other Non-Current Assets for CADL at $300000.0 in Q4 2023, $139000.0 in Q3 2023, and $300000.0 in Q2 2023.